Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy

Cancer

Volumn 77, Issue 8, 1996, Pages 1515-1523

  Pollack, Alan ^a,c   Lankford, Scott ^a   Zagars, Gunar K ^a   Babaian, R Joseph ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NONE   (United States)

Author keywords

prognosis; prostate specific antigen density; radiotherapy; transrectal ultrasound

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0029866763     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19960415)77:8<1515::aid-cncr14>3.3.co;2-4     Document Type: Article

References (19)

1. Zentner PG, Pao LK, Benson MC, McMahon DJ, Schiff PB. Prostate-specific antigen density: a new prognostic indicator for prostate cancer. Int J Radiat Oncol Biol Phys 1993;27:47-58.
2. Corn BW, Hanks GE, Lee WR, Bonin SR, Hudes G, Schultheiss T. Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformai radiotherapy. J Urol 1995;153:1855-9.
3. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32:293-306.
4. Zagars GK, Geara FB, Pollack A, von Eschenbach AC. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome following radiation therapy. Cancer 1994;74:1904-12.
5. Beahrs OH, Henson DE, Hutter RVP, and Kennedy BJ, editors. American Joint Committee on Cancer, Manual for Staging of Cancer. 4th edition. Philadelphia: J B Lippincott, 1992:181-3.
6. Benson MC, Whang IS, Olsson A, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817-21.
7. Littrup PJ, Williams CR, Egglin TK, Kane RA. Determination of prostate volume with transrectal US for cancer screening. Part II. Accuracy of in vitro and in vivo techniques. Radiology 1991;179:49-53.
8. Pollack A, Zagars GK, Kopplin S. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Cancer 1995;32:13-20.
9. Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Cancer 1987;60:1489-99.
10. Pollack A, Zagars GK, Starkschall G, Childress CH, Kopplin S, Boyer AL, et al. Conventional versus conformai radiotherapy for prostate cancer: preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996;34:555-64.
11. Steel RGD, Torrie JH. Principles and procedures of statistics: a biometrical approach. New York: McGraw-Hill, 1980.
12. Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991:179-268.
13. Harris EK, Albert A. Survivorship analysis for clinical studies. New York: Marcel Dekker, Inc., 1991:5-125.
14. Rommel FM, Agusta VE, Breslin JA, Huffnagle HW, Pohl CE, Seiber PR, et al. The use of prostate specific antigen and prostate specific antigen density in the diagnosis of prostate cancer in a community based urology practice. J Urol 1994;151:88-93.
15. Bretton PR, Evans WP, Borden JD, Castellanos RD. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma. Cancer 1994;74:2991-5.
16. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993;11:2158-66.
17. Zeitman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-5.
18. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J Clin Oncol 1995;13:464-9.
19. Zagars GK, Pollack A, von Eschenbach AC. Prostate cancer and radiation therapy - the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995;33:23-35.